Taft attorneys Andrew A. Alul, Stephen R. Auten, Joseph M. Bennett-Paris, Ph.D., Jane S. Berman and Richard T. Ruzich authored chapters in the 2nd edition of "ANDA Litigation: Strategies and Tactics for Pharmaceutical Patent Litigators," which was published in May by ABA Publishing. Auten and Ruzich also served as associate editors for the book.
Alul, Bennett-Paris and Ruzich wrote Chapter 6, titled “Use of Reissue Proceedings in Hatch-Waxman Litigation.” Auten and Berman penned Chapter 8, “Examining Subject-Matter Jurisdiction over Declaratory Judgment Claims Filed in Combination with Patent Infringement Claims under Section 271(e)(2)(A).” For more information or to order the book, click here.
Alul focuses his practice on intellectual property litigation and counseling, particularly pharmaceutical drug patent litigation and regulatory litigation involving the U.S. Food and Drug Administration (FDA). He has extensive experience litigating cases brought under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act for pharmaceutical products and under the Administrative Procedures Act.
Auten is head of Taft's Pharmaceutical and Life Sciences Litigation practice. He is a widely recognized and seasoned attorney in Hatch-Waxman and biosimilar| matters, including related patent litigation, and is followed by key industry leaders (brand and generic alike), law firms, analysts, educators and others on his LinkedIn blog "Hatch Waxman ANDA Litigation Forum," which has more than 6,000 members worldwide. He currently represents clients primarily in the areas of Paragraph IV design strategies, Hatch-Waxman litigation and biosimilar market opportunities.
Bennett-Paris is a partner in Taft’s Pharmaceutical and Life Sciences Litigation practice. He counsels clients in all areas of patent law, including patent prosecution, non-infringement, patentability, freedom-to-operate, invalidity and licensing. His practice primarily focuses on biotechnology, pharmaceutical, chemistry, and most recently, biosimilars.
Berman is a registered patent attorney and a member of Taft’s Intellectual Property group. She has broad experience in the prosecution, enforcement, licensing and transfer of intellectual property, including patents, trade secrets, trademarks and copyrights, and has substantial experience advising on the intellectual property aspects of complex corporate and financial transactions, including acquisitions, licensing, commercial lending, private equity finance and restructuring.
Ruzich is an internationally recognized patent attorney who focuses on complex patent litigation, representing generic pharmaceutical companies in Abbreviated New Drug Application (ANDA) litigation under the Hatch-Waxman statutory framework. An accomplished trial and appellate advocate, registered patent attorney and frequent lecturer and author, he is known worldwide for his legal work on behalf of his generic clients, including biosimilars sponsors. His experience covers the entire lifecycle spectrum from product selection, Paragraph IV development and through to market entry, including at-risk launches.